Solvias Plans to Open New Biotech Site in California, USA
Introduction:
Solvias plans to expand its global network to build a new biotech site in North California, USA.
Features:
The new 50,000-square-foot facility will expand analytical testing services for life science organisations, addressing the growing use and development of cell and gene therapies (CGTs) and biologics.
This state-of-the-art centre will offer crucial cell-based potency assays, advanced next-gen sequencing (NGS) capabilities, and a variety of related testing services supporting multiple biologic modalities.
From its inception, it will facilitate the characterisation and release testing of CGTs and other advanced therapies, including adeno-associated virus (AAV) gene therapies, mRNA therapies, and antibody-drug conjugates.
The new centre will be equipped with state-of-the-art analytical instrumentation, advanced laboratory automation technology, and integrated digital management systems.
The new facility is expected to be completed in 2025. It will create over 170 serving as hub for large molecule analytical services.
Specifications:
Name Solvias
Type New Construction
Year 2025
